The Centre for Commercialization of Regenerative Medicine Australia and BioCurate enter into a Memorandum of Understanding (MoU) to accelerate the translation of therapies in the Australian regenerative medicine
Innovative and curative treatments push the limits of the government’s finite reimbursement purse. This pressing issue brings to light the growing concerns surrounding the reimbursement of cell therapies
It was a sunny Philadelphia that greeted the 11th Business of Regenerative Medicine Symposium. Hosted at the University of Pennsylvania’s Similow Center for Translational Research, the two-day symposium
Nerve (neuropathic) pain affects one in twenty Australians. For some, it’s a frustration, for others it’s nothing short of debilitating. What’s worse, nerve damage often cannot be entirely
In 2008, mesenchymal stem cells were not gracing the front page of prestigious academic journals as they do today. Yet the founders of Regeneus knew differently. A company
As stem cell therapies move through clinical trials and get closer to the clinic, they are giving rise to new challenges, primarily around costs and the likelihood of
From Biotech Daily, Friday February 9, 2018 By Tim Boreham ASX code: CYP Share price: 82 cents; Shares on issue: 90,057,248 Market cap: $73.8 million Chief executive officer: Dr
A leading Australian stem and regenerative medicine company, Cynata Therapeutics was established with the objective of developing therapeutic products using the Cymerus™ technology. With innovative research, translation and
Despite Australia’s reliable and robust regulatory environment addressing drugs and medical technologies in market, unproven and expensive stem cell therapies have been able to expand and flourish across
